Plamaz-Schatz Coronary Stenting Accomplished by High Pressure Balloon Dilatation without Anticoagulation.
10.4070/kcj.1996.26.5.935
- Author:
Myeong Ki HONG
;
Sang Sig CHEONG
;
Jin Woo KIM
;
Sang Kon LEE
;
Cheol Whan LEE
;
Jae Joong KIM
;
Seong Wook PARK
;
Seung Jung PARK
- Publication Type:Original Article
- Keywords:
Stent;
Anticoagulation
- MeSH:
Aspirin;
Dilatation*;
Humans;
Length of Stay;
Retrospective Studies;
Stents*;
Thrombosis;
Ticlopidine;
Ultrasonography;
Warfarin
- From:Korean Circulation Journal
1996;26(5):935-940
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The clinical use of intracoronary stents is impeded by the risk of subacute stent thrombosis and complications associated with the anticoagulant regimen. The use of high pressure balloon dilatations and confirmation of adequate stent expansion by intravascular ultrasound provide assurance that anticoagulation therapy can be safely omitted. Therefore, we evaluated the effect of anticoagulation of subacute thrombosis sfter stenting retrospectively on a consecutive series of patients who received palmaz-Schatz coronary stents with high pressure balloon dilatation. METHOD: From March 1995 to August 1995, 62 patients underwent Palmaz-Schatz coronary stent implantation. After deploying stents successfully, high pressure overdilatation of the stents was performed in all patients. According to post-stent anticoagulation, 32 patients received aspirin 200 mg/day, ticlopidine 500 mg/day and warfarin for two months, 30 patients received aspirin and ticlopidine. RESULTS: The clinical or angiographic variables were not significantly different between the two groups. There was no acute or subacute thrombosis in the two groups. The hospital stay after stenting was significantly shorter in the patients without antcoagulation than in patients with anticoagulation. CONCLUSION: The Palmaz-Schatz stent can be safely implanted without anticoagulation provided that stent expansion is daequate by the use high pressure balloon dilatation This technique significantly reduces hospital time and vascular complications and has a low stent thrombosis rate.
